Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/autotransplantation and who were conventionally treated

Journal of Clinical Oncology

Volumn 14, Issue 7, 1996, Pages 2167-2173

  Blade J ^a   San Miguel, J F ^a   Fontamllas, M ^a   Alcala A ^a   Maldonado, J ^a   Garcia Conde J ^a   Conde, E ^a   Conzalez Brito G ^a   Moro, M J ^a   Escudero, M L ^a   Trujillo, J ^a   Pascual, A ^a   Rozman, C ^a   Estape J ^a   Montserrat, E ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; MELPHALAN; PREDNISONE; VINCRISTINE;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 8944237979     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.7.2167     Document Type: Article

References (46)

1. Alexanian R, Haut A, Khan AU, et al: Treatment for multiple myeloma: Combination chemotherapy with different melphalan dose regimens. JAMA 208:1680-1685, 1969
2. Bergsagel DE: Chemotherapy of myeloma, in Malpas JS, Bergsagel DE, Kyle RA (eds): Myeloma. Biology and Management. Oxford, United Kingdom, Oxford University, 1995, pp 273-306
3. Salmon SE, Haut A, Bonnet JD, et al: Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: A Southwest Oncology Group study. J Clin Oncol 1:456-461, 1993
4. MacLennan ICM, Chapman C, Dunn J, et al: Combined chemotherapy with ABCM versus melphalan for the treatment of myelomatosis. Lancet 339:200-205, 1992
5. Pavlovsky S, Corrado C, Santarelli MT, et al: An update of two randomized trials in previously untreated multiple myeloma comparing melphalan and prednisone versus three- and five-drug combinations: An Argentine Group for the Treatment of Acute Leukemia study. J Clin Oncol 6:769-775, 1988
6. Österborg A, Ahre A, Björkholm M, et al: Alternating combination chemotherapy (VCMP/VBAP) is not superior to melphalan/ prednisone in the treatment of multiple myeloma patients stage III: A randomized study from MGCS. Eur J Haematol 43:54-62, 1989
7. Boccadoro M, Marmont F, Tribalto M, et al: Multiple myeloma: VCMP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisolone even in high-risk patients. J Clin Oncol 9:444-448, 1991
8. Bladé J, San Miguel JF, Alcalá A, et al: Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: A randomized multicentric study of 487 patients. J Clin Oncol 11:1165-1171, 1993
9. Gregory WM, Richards MA, Malpas JS: Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: An overview of published trials. J Clin Oncol 10:334-342, 1992
10. Samson D, Gaminara E, Newland A, et al: Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet 2:882-885, 1989
11. Gore ME, Selby PJ, Viner C, et al: Intensive treatment of multiple myeloma and criteria for complete remission. Lancet 2:879-881, 1989
12. Lokhorst HM, Th. Meuwissen OJ, Verdonk LF, et al: High-risk multiple myeloma treated with high-dose melphalan. J Clin Oncol 10:47-51, 1992
13. Attal M, Huguet F, Schlaifer D, et al: Intensive combined therapy for previously untreated aggressive myeloma. Blood 79:1130-1136, 1992
14. Harousseau JL, Milpied N, Laporte JP, et al: Double-intensive therapy in high-risk multiple myeloma. Blood 79:2827-2833, 1992
15. Anderson KC, Andersen J, Soiffer R, et al: Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. Blood 82:2568-2576, 1993
16. Gianni AM, Tarella C, Bregni M, et al: High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma. J Clin Oncol 12:503-509, 1994
17. Dimopoulos MA, Alexanian R, Przepiorka D, et al: Thiotepa, busulfan, and cyclophosphamide: A new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood 82:2324-2328, 1993
18. Jagannath S, Vesole DH, Glenn L, et al: Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood 80:1666-1672, 1992
19. Attal M, Harousseau JL, Stoppa AM, et al: High-dose therapy in multiple myeloma: a prospective randomized study of the "Intergroup Francais du Myelome" (IFM). Blood 84:386a, 1994 (suppl 1, abstr)
20. Fermand JP, Ravaud Ph, Chevret S, et al: High-dose therapy and autologous blood stem cell transplantation (ABSCT) in multiple myeloma (MM): Preliminary results of a randomized clinical trial in 167 patients. Blood 84:535a, 1994 (suppl 1, abstr)
21. Chronic Leukemia-Myeloma Task Force: National Cancer Institute: Proposed Guidelines for protocol studies. II. Plasma cell myeloma. Cancer Chemother Rep 4:145-158, 1973
22. Kyle RA: Monoclonal gammopathy of undetermined significance: natural history in 241 cases. Am J Med 64:814-826, 1978
23. Kyle RA, Greipp PR: Smoldering multiple myeloma. N Engl J Med 302:1347-1349, 1980
24. Bladé; J, San Miguel JF, Sanz-Sanz MA, et al: Treatment of melphalan-resistant multiple myeloma with vincristine, BCNU, doxorubicin and high-dose dexamethasone (VBAD). Eur J Cancer 29A:57-60, 1993
25. San Miguel JF, Moro M, Bladé J, et al: Combination of Interferon and dexamethasone in refactory multiple myeloma. Hematol Oncol 5:185-189, 1990
26. Kaplan GL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
27. 2/E in the log-rank test for survival data or tumour incidence data. Biometrics 29:579-584, 1972
28. Cox DR: Regression models and life tables. J R Stat Soc 34:187-220, 1972
29. Buckman R, Cuzik J, Galton DAG: Long-term survival in myelomatosis. Br J Haematol 52:589-599, 1982
30. Kyle RA: Long-term survival in multiple myeloma. N Engl J Med 308:314-316, 1983
31. Alexanian R: Ten-year survival in multiple myeloma. Arch Intern Med 145:2073-2074, 1985
32. Dutcher JP, Wiernik PH: Long-term survival of a patient with multiple myeloma -a cure? A case report. Cancer 53:2069-2071, 1984
33. Kyle RA: IgD myeloma: A cure at 21 years. Am J Hematol 29:41-43, 1988
34. Cunningham D, Paz-Ares L, Milan S, et al: High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 12:759-763, 1994
35. Harouseau JL, Attal M, Divine M, et al: Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: A report of the French Registry on autologous transplantation in multiple myeloma. Blood 85:3077-3085, 1995
36. Alexanian R, Dimopoulos MA, Hester J, et al: Early myeloablative therapy for multiple myeloma. Blood 84:4278-4282, 1994
37. Vesole DH, Barlogie B, Jagannath S, et al: High-dose therapy for refractory multiple myeloma: Improved prognosis with better supportive care and double transplants. Blood 84:950-956, 1994
38. Gahrton G: Allogeneic bone marrow transplantation in multiple myeloma. Proceedings of the Fifth International Workshop on Multiple Myeloma, La Baule, France, September 10-13, 1995, p 3.129
39. Gahrton G, Tura S, Ljungman P, et al: Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 13:1312-1322, 1995
40. Björkstrand B, Goldstone AH, Ljungman P, et al: Prognostic factors in autologous stem cell transplantation for multiple myeloma: An EBMT Registry study. Leuk Lymph 15:265-272, 1994
41. Barlogie B, Jagannath S, Vesole D, et al: Autologous and allogeneic transplants for multiple myeloma. Semin Hematol 32:31-44, 1995
42. Anderson KC: Who benefits from high-dose therapy for multiple myeloma?. J Clin Oncol 13:1291-1296, 1995
43. Jagannath S: Total therapy for newly diagnosed multiple myeloma. Proceedings of the Fifth International Workshop on Multiple Myeloma, La Baule, France, September 10-13, 1995, p 337
44. Björkstrand B, Ljungman P, Bird JM, et al: Double high-dose intensification with autologous hematpoietic stem cell transplantation can induce long-term molecular remissions in multiple myeloma. Proceedings of the Fifth International Workshop on Multiple myeloma. La Baule, France, September 10-13, 1995, p 3.98
45. Björkstrand B: 474 autotransplants in multiple myeloma. Results of the EBMT. Proceedings of the Fifth International Workshop on Multiple Myeloma. La Baule, France, September 10-13, 1995, p 3.32
46. Cunningham D, Powles R, Malpas JS, et al: A randomized trial of maintenance therapy with Intron A following high dose melphalan and ABMT in myeloma. Proc Am Soc Clin Oncol 12:364, 1993 (abstr)